Mark Biagi

Development of High-Level Echinocandin Resistance in a Patient With Recurrent Candida auris Candidemia Secondary to Chronic Candiduria

Mark Biagi, Nathan P. Wiederhold, Connie Fe C. Gibas et al. · Open Forum Infectious Diseases · 2019 · 127 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +17

Exploring Aztreonam in Combination with Ceftazidime-Avibactam or Meropenem-Vaborbactam as Potential Treatments for Metallo- and Serine-β-Lactamase-Producing <i>Enterobacteriaceae</i>

Mark Biagi, Ting Wu, Migyung Lee et al. · Antimicrobial Agents and Chemotherapy · 2019 · 104 citations · Full text

Pharmacy, Microbiology, Pharmacotherapy +17

Activity of Potential Alternative Treatment Agents for Stenotrophomonas maltophilia Isolates Nonsusceptible to Levofloxacin and/or Trimethoprim-Sulfamethoxazole

Mark Biagi, X. Tan, Tian-Shung Wu et al. · Journal of Clinical Microbiology · 2019 · 60 citations · Full text

Pharmacy, Infectious Diseases, Microbiology +16

Activity of Cefiderocol Alone and in Combination with Levofloxacin, Minocycline, Polymyxin B, or Trimethoprim-Sulfamethoxazole against Multidrug-Resistant Stenotrophomonas maltophilia

Mark Biagi, A. Vialichka, M. Jurkovic et al. · Antimicrobial Agents and Chemotherapy · 2020 · 58 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +16

Clinical Outcomes of Eravacycline in Patients Treated Predominately for Carbapenem-Resistant Acinetobacter baumannii

Sara Alosaimy, Taylor Morrisette, Abdalhamid M Lagnf et al. · Microbiology Spectrum · 2022 · 54 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +16